Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine blocks voltage‑gated sodium channels on peripheral nerves, preventing the initiation and propagation of action potentials. This interruption stops pain signals from reaching the brain. The epinephrine component constricts local blood vessels, limiting systemic absorption and extending the duration of the anesthetic effect.

The appropriate dose of Orabloc is determined by the prescribing dentist or oral surgeon based on the specific procedure, patient age, weight, and medical history. Clinicians calculate the volume needed to achieve adequate anesthesia while staying within recommended maximum limits for articaine and epinephrine.

The safety of Orabloc in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful evaluation by the treating clinician.

To request Orabloc, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Orabloc contains articaine, which has a higher lipid solubility and faster onset than many amide anesthetics such as lidocaine. The addition of epinephrine prolongs its effect. Compared with lidocaine‑based products, articaine may achieve deeper anesthesia with a slightly lower total dose, but clinicians must still monitor for similar cardiovascular and allergic risks.

Orabloc should be stored at room temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct light and moisture. Do not freeze or shake the vial, and keep it out of reach of children.

Orabloc is supplied as a sterile solution for intraoral injection. The clinician injects the appropriate volume into the targeted tissue (e.g., periodontal ligament, mucosal area, or nerve block site) using standard dental syringes. The onset of anesthesia typically occurs within 1–3 minutes.

Serious risks include allergic reactions ranging from rash to anaphylaxis, prolonged numbness beyond 24 hours, and cardiovascular events such as hypertension or tachycardia caused by the epinephrine component. Rarely, methemoglobinemia can develop, especially in susceptible individuals.

Patients with a known hypersensitivity to articaine, other amide‑type local anesthetics, or epinephrine should not receive Orabloc. It is also contraindicated in individuals with uncontrolled severe hypertension, certain cardiac arrhythmias, or those taking non‑selective MAO inhibitors without appropriate medical supervision.